Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma

Core Insights - Verastem Oncology announced positive updated efficacy and safety data from GenFleet Therapeutics' Phase 1/2 monotherapy study of GFH375, an oral KRAS G12D inhibitor for advanced pancreatic ductal adenocarcinoma [1] Company Summary - Verastem Oncology is focused on developing new medicines for patients with RAS/MAPK-pathway-driven cancers [1] - GFH375, also known as VS-7375 outside of China, targets KRAS G12D mutations in advanced pancreatic ductal adenocarcinoma [1] Study Details - The study involved 59 heavily pre-treated patients, indicating a significant patient population for evaluating the drug's efficacy and safety [1]